Intestinal uptake and transport of albumin nanoparticles:potential for oral delivery by Hashem, Lina et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.2217/nnm-2018-0029
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Hashem, L., Swedrowska, M., & Vllasaliu, D. (2018). Intestinal uptake and transport of albumin nanoparticles:
potential for oral delivery. Nanomedicine, 13(11), 1255-1265. https://doi.org/10.2217/nnm-2018-0029
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
 1 
Abstract  
Aim: To explore the potential of albumin nanoparticles for oral drug delivery. Methods: sub-
150 nm human serum albumin nanoparticles were fabricated via a desolvation technique. 
Nanoparticle cell uptake and epithelial translocation were tested in Caco-2 monolayers, 
while comparing with albumin solution. Results: data suggest epithelial transcytosis of 
albumin, applied in solution form, via neonatal Fc receptor (FcRn). Cell uptake of albumin 
nanoparticles demonstrated behaviours indicating a different cell uptake pathway compared 
to albumin solution. Importantly, application of equivalent concentrations of albumin solution 
or nanoparticles resulted in higher epithelial transport capacity of the latter, suggesting 
improvement of intestinal delivery via nanoformulation. Conclusion: This study highlights for 
the first time that simply-fabricated, non-toxic human serum albumin nanoparticles may find 
application in oral drug delivery.  
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Introduction 
Oral administration is the ultimate drug delivery route due to convenience and patient 
compliance, but is currently not viable for advanced therapeutics, such as biologics or 
complex (e.g. targeted) nanomedicines. Both biotherapeutics and nanomedicines suffer from 
poor penetration across the formidable barrier of the intestinal epithelium. Considering the 
individual components of the overall gastrointestinal (GI) barrier to systemic drug absorption, 
significant progress has been made in solid dosage systems that protect the therapeutic 
from degradation, as well as mucus-penetrating materials. However, overcoming the 
formidable epithelial barrier remains the most challenging aspect of oral delivery of biologics 
and nanomedicines.  
 
Current approaches to improve oral delivery typically employ ‘absorption enhancers’ that 
non-selectively disrupt and increase the intestinal permeability. However, safety concerns, 
such as those associated with many surfactants [1], have hindered the clinical translation of 
this approach in general. Key to safe and effective oral delivery of biologics and 
nanomedicines is the engineering of systems capable of delivering the drug selectively 
across the intestinal mucosa without disrupting this physiologically important barrier. This 
has led to efforts to explore biological transport processes as potential routes to deliver 
therapeutics across the intestinal barrier. These approaches typically rely on appropriate 
formulation of a drug, a suitable drug carrier, usually nanocarrier, and a ligand to target the 
system towards the biological receptor and transport process of choice. The combination of 
such requirements leads to complexity of systems and difficulties in achieving a compromise 
between bioactivity and manufacturability.   
 
The use of albumin nanoparticles in drug delivery has recently increased significantly, since 
as an endogenous material, albumin has the combination of properties of an ideal drug 
carrier, including long half-life, serum stability, biodegradability, lack of toxicity, non-
immunogenicity and water solubility [2]. Serum albumin is known for its remarkable ligand 
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binding capacity. Specifically, it contains eleven specific binding sites for hydrophobic 
compounds [3]. Many drugs and endogenous molecules are known to bind to albumin; 
therefore, albumin nanoparticles can serve as depot systems, with drug release achieved 
naturally by protease digestion. The combination of the desirable properties of albumin and 
the simple fabrication approach of albumin nanoparticles explains the recent focus on these 
systems, particularly for targeted delivery of cancer therapeutics [4, 5].  
 
Albumin nanocarriers could present a new and simple way of achieving transcytosis-
targeted nanocarriers for oral drug delivery. Because the biological transport mechanism of 
albumin is expressed in the intestinal epithelium, the albumin nanocarrier could serve both 
as a drug carrier and a ‘transport-enabling’ entity, bypassing the requirement for another 
component (e.g. transcytosis ligand). This would make the overall drug delivery system 
simpler and less expensive, in addition to improving drug loading and potentially drug 
transport properties.  
 
This study explored whether biological transport of albumin demonstrates potential for 
intestinal drug delivery. The work reports on the transcytosis of albumin across differentiated 
Caco-2 monolayers as an in vitro intestinal model, while probing the biological transport 
mechanism of albumin. We then fabricated sub-150 nm albumin nanoparticles of low 
polydispersity and investigated their uptake and transport across polarised Caco-2 cell 
monolayers. We show that albumin nanoparticles displayed a different cell uptake and 
transintestinal transport behaviour to albumin in solution, suggesting a shift in the trafficking 
route with nanoformulation. A notably higher amount of albumin traversed Caco-2 
monolayers following the application of albumin nanoparticles, as compared to equivalent 
concentration of albumin solution, suggesting, significantly, improvement of transintestinal 
delivery via nanoformulation.  
 
Materials & methods  
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Materials  
Fluorescein isothiocyanate (FITC)-labelled human serum albumin was purchased from 
Abcam (UK). Glutaraldehyde, Hank’s Balanced Salt Solution (HBSS; with sodium 
bicarbonate, without phenol red), Dulbecco’s Modified Eagle’s Medium and all other 
reagents, unless otherwise stated, were purchased from Sigma (UK). Goat, anti-human 
FcRn antibody and donkey, anti-goat TRITC-IgG were obtained from Santa Cruz (USA). 
Prolong Gold Antifade mountant was purchased from ThermoFisher Scientific (USA). Caco-
2 cells were purchased from the European Collection of Cell Cultures (ECACC) and used 
between passages 52-55. Transwell permeable inserts of 12 mm diameter, polycarbonate 
filters and 0.4 μm pore size were obtained from Costar (USA). 3-(4,5-dimethylthiazol-2-yl)-
5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent, which is 
commercially known as 'CellTiter 96 AQueous One Solution Cell Proliferation Assay', was 
obtained from Promega (USA).  
 
Fabrication of albumin nanoparticles  
Albumin nanoparticles were prepared by the established desolvation technique. Briefly, 
albumin or FITC-albumin were dissolved in Tris-HCl (pH 6.9) to make a 1% w/v solution. The 
pH was then adjusted to pH 9.0 using NaOH. Desolvation of this solution was achieved by 
constant stirring and the dropwise addition of 0.8 ml ethanol manually using a syringe, at 
room temperature. After desolvation, 2 µL of 25% glutaraldehyde was added to induce 
particle cross-linking. The crosslinking process was performed under stirring of the 
suspension over a 24-hour period at room temperature.  
 
Albumin nanoparticle characterisation 
After preparation of albumin nanoparticles in water and HBSS the average particle size and 
polydispersity, was measured by dynamic light scattering (DLS) using a Malvern zetasizer 
(Malvern Instruments Ltd., Malvern, UK). The samples were diluted 1 in 20 with purified 
water, then measured at a temperature of 25°C and a scattering angle of 173°. Albumin 
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nanoparticles made in Tris-HCl at pH 9.0, 9.5 and 10.0 were characterised using the same 
technique; three readings were taken for each sample. To assess reproducibility of 
nanoparticles produced in Tris-HCl at pH 9.0 three batches of albumin nanoparticles were 
characterised; three readings were taken for each sample. Then to measure the stability of 
albumin nanoparticles in different biological buffers, the nanoparticles were diluted 1 in 20 
with purified water, PBS or HBSS and three readings were taken at each time point (0, 30, 
60, 90 and 120 minutes). 
 
Cell culture  
Caco-2 cells were cultured using DMEM. Cells were seeded on Transwell permeable plates 
at 105 cells/cm2. Culture medium was replaced every other day. Caco-2 cells were typically 
cultured on permeable supports for 21–23 days, prior to their use as polarized cell layers.  
 
For ‘saturation study’, ‘IgG competition’, ‘albumin nanoparticle competition’ and ‘albumin 
nanoparticle uptake’ studies, polarised cells were equilibrated in HBSS for 45 min. 
Transepithelial electrical resistance (TEER) was then measured to confirm cell monolayer 
integrity; cells typically displayed TEER between 700-1200 Ω/cm2 and those below 500 
Ω/cm2 were not used. 
 
Nanoparticle toxicity  
The MTS assay was employed to assess the effect of albumin nanoparticles on Caco-2 cell 
viability. Cells were seeded on 96-well plates at a density of 5,000 cells per well and cultured 
overnight in DMEM. Culture medium was removed and replaced by albumin nanoparticle 
suspensions diluted in HBSS at concentrations of 17.5, 35, 70, 140 and 280 µg/ml (albumin 
content). Triton X-100 (1% v/v) was employed as a positive control (assumed to induce 
100% cell death) and HBSS as negative control (assumed no cell death). Cells were then 
incubated (at 37 ºC, 5% CO2) with the samples and controls for three hours. This was 
followed by sample removal and cell washing with PBS. MTS solution reagent was added to 
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each well (20 μl) and cells incubated (at 37 ºC, 5% CO2) for 1.5 hours. Absorbance was 
recorded at 490 nm using a 96-well plate reader.  
 
FcRn expression by Caco-2 cells  
Polarised Caco-2 monolayers were fixed in paraformaldehyde, washed with PBS and 
permeabilised by incubating with Triton X-100 (1% v/v in PBS) for approximately 10 min. 
Cells were washed again and incubated for 1 hour with BSA in PBS (1% w/v). Goat, anti-
human FcRn primary antibody was diluted to 10 µg/ml in 1% w/v BSA/PBS and incubated 
with the cells for 30-60 min at room temperature. Cells were then washed extensively and 
treated with donkey, anti-goat TRITC-IgG (secondary antibody, diluted according to 
supplier's instructions in 1% BSA/PBS) for 30-60 min. Thereafter, cells were washed 
extensively and filters excised and mounted on a glass slide (using a DAPI-containing 
ProLong® Gold antifade mounting medium) for confocal imaging. Control experiments were 
conducted where the cells were treated with the secondary antibody only. Confocal imaging 
was conducted using a Leica TCS SP2 system mounted on a Leica DMIRE2 inverted 
microscope. 
 
Albumin uptake saturation 
FITC-albumin was applied to the apical side of Caco-2 monolayers in HBSS at 8 µg/ml, 40 
µg/ml and 200 µg/ml for two hours. FITC-albumin uptake was measured by permeabilising 
the polarised Caco-2 cells using Triton X-100 (1% v/v; 10 min incubation) and determining 
the fluorescence intensity of the samples (quantified via a calibration curve).  
 
Albumin and IgG permeability 
Human serum FITC-albumin was applied to the apical side of Caco-2 monolayers in HBSS 
at 40 µg/ml and human IgG at 1 µg/ml. Permeability was measured by sampling the basal 
solution every 20 min for two hours. FITC-albumin was quantified by fluorescence. IgG was 
quantified by ELISA using NUNCImmuno 96 MicroWell™ (NUNC, Denmark) plates, 1% BSA 
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w/v in PBS as the blocking buffer, horseradish peroxidase (HRP)-conjugated anti-human 
IgG (The Binding Site, UK), diluted 1:1000 in blocking buffer as the detection antibody and 
3,3,5,5-tetramethylbenzidine (TMB, Autogen Bioclear Ltd, UK) as the substrate; the reaction 
was stopped using 2.5 M sulphuric acid (20 μl) and absorbance determined at 450 nm. 
 
Albumin uptake and permeability competition studies   
40 µg/ml FITC-albumin was applied to polarised Caco-2 monolayers in combination with 100 
µg/ml IgG in HBSS. FITC-albumin permeability was measured by sampling the basal 
solution every 20 min for two hours. FITC-albumin uptake was measured by permeabilising 
the polarised Caco-2 cells using Triton X-100 (1% v/v; 10 min incubation) and quantitation 
by fluorescence.  
 
FITC-albumin at 40 µg/ml was applied to polarised Caco-2 monolayers together with 140 
µg/ml albumin nanoparticles (unlabelled) in HBSS. FITC-albumin permeability and uptake 
were determined as above.  
 
Albumin nanoparticle uptake and epithelial transport  
FITC-albumin nanoparticles were applied to polarised Caco-2 monolayers at 40 and 200 
µg/ml (albumin content) in HBSS. Additionally, to determine FcRn involvement in the uptake 
and transport process of FITC-albumin nanoparticles, they were applied at 40 µg/ml in 
combination with 100 µg/ml IgG in HBSS. Transepithelial transport was determined by 
regular sampling of the basal solution (every 20 min for two hours) and uptake following 
permeabilisation using Triton X-100 (1% v/v; 10 min incubation).  
 
Cell uptake of FITC-albumin nanoparticles was also determined qualitatively using confocal 
microscopy. FITC-albumin nanoparticles were applied to polarised Caco-2 monolayers at 40 
µg/ml in HBSS for two hours. Cell monolayers were then washed with PBS and fixed using 
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4% w/v paraformaldehyde (10 min incubation). Cells were then stained with DAPI-containing 
ProLong® Gold antifade mounting medium.  
 
Statistical analysis  
Student’s t-test was performed for comparisons of two group means, while one way analysis 
of variance (ANOVA) was utilised for comparison of three or more group means. P value of 
<0.05 was considered statistically significant. **** and * indicate p < 0.0001 and p < 0.05, 
respectively, whereas “ns” indicates nonsignificant. Statistical analysis was conducted using 
GraphPad Prism® Software.   
 
Results 
Nanoparticle characterisation  
Albumin nanoparticles prepared in Tris-HCl (pH 9.0) were tested for stability, in terms of 
size, in water and biologically-relevant buffers, PBS and HBSS. Figure 1 shows albumin 
nanoparticle size following incubation in these conditions for up to two hours. The data show 
that albumin nanoparticle size remained stable with no statistically significant changes in the 
mean diameter over the two-hour incubation period in all conditions. The mean nanoparticle 
diameter at 0 hour and 2 hours in HBSS, in which nanoparticles were later applied to the 
cells, was 142.3 ± 1.3 nm and 146.0 ± 2.1 nm, respectively. The average polydispersity 
index at 0 hour and 2 hours was 0.2 ± 0.02 and 0.1 ± 0.01, respectively.  
  
Figure 1.  
 
Nanoparticle toxicity  
The effect of albumin nanoparticles on relative cell viability over a concentration range 17.5-
280 µg/ml (albumin content) is shown in Figure 2. Albumin nanoparticle suspensions up to 
140 µg/ml albumin concentration showed no significant negative effect on Caco-2 viability, 
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while albumin nanoparticle suspensions of 280 µg/ml exhibited a 50 (±15.3%) reduction in 
relative cell viability (statistically significant).  
 
Figure 2.  
 
FcRn expression by Caco-2 cells  
Red fluorescence signal due to donkey, anti-goat TRITC-IgG, was distributed in the regions 
around the nuclei. This fluorescence was only observed in cells incubated with both, primary 
and secondary antibodies (Figure 3A & B). In control cells where incubation with the primary 
antibody was omitted (i.e. cells were exposed to secondary only) no red fluorescence was 
detected (Figure 3C). 
 
Figure 3.  
 
Albumin uptake saturation 
To assess whether albumin uptake by Caco-2 cells follows a receptor-mediated route, 
uptake was determined following the application of different concentrations. Figure 4 shows 
that albumin uptake increased modestly, from 100 ng to 114 ng per cell monolayer, as the 
concentration applied apically increased from 8 to 40 µg/ml. Further increase in the applied 
albumin concentration from 40 to 200 µg/ml did not enhance albumin uptake, with uptake 
levels reaching 110 ng per cell monolayer.   
 
Figure 4.  
 
Albumin and IgG permeability 
In this set of experiments, we compared the permeability of albumin across Caco-2 
monolayers with that of IgG as two substrates for the FcRn receptor. Figure 5 shows that 
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albumin displayed a markedly higher permeability compared to IgG, with basal levels 
reaching approximately 68 ng compared to IgG, which amounted to 2.7 ng after two hours.  
 
Figure 5.  
 
Albumin uptake and permeability competition studies   
To obtain more insight into the internalisation and transport route of albumin and to 
determine whether albumin nanoparticles follow the same trafficking as albumin in solution, 
studies were conducted whereby albumin solution was applied to the cells in combination 
with IgG or albumin nanoparticles. The data in Figure 6A show that IgG more than halved 
the uptake of albumin, from 49 to 21 ng per cell monolayer (p=0.020). On the other hand, 
application of unlabelled albumin nanoparticles alongside FITC-albumin, did not suppress 
the uptake of the latter (statistically insignificant difference).  
 
Considering apical-to-basal permeability of albumin, Figure 6B indicates that co-application 
with IgG somewhat reduced FITC-albumin permeability, particularly in the second hour of 
the experiment, although this effect did not reach statistical significance. Albumin 
nanoparticles did not influence FITC-albumin permeability across Caco-2 monolayers.   
 
Figure 6.  
 
Albumin nanoparticle uptake and epithelial transport  
FITC-albumin nanoparticles were applied to Caco-2 monolayers at different concentrations 
to determine saturation and in combination with IgG in order to establish whether albumin 
nanoparticles are internalised via the FcRn pathway. Figure 7A indicates that FITC-albumin 
nanoparticle uptake was notably higher following application at 200 µg/ml (183 ng per cell 
monolayer) relative to the lower concentration of 40 µg/ml (69 ng per cell monolayer). IgG on 
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the other hand did not influence the internalisation of FITC-albumin nanoparticles (64 ng per 
cell monolayer).  
 
Regarding FITC-albumin nanoparticle transport, Figure 7B shows that FITC-albumin 
nanoparticles traversed polarised Caco-2 monolayers and the rate or final amount 
accumulated on the basolateral side was not influenced by the applied concentration (40 
versus 200 µg/ml) or co-application with IgG. Up to 380 ng of FITC-albumin, formulated as 
nanoparticles, permeated across the cell monolayers in two hours.  
 
Figure 7.  
 
Confocal microscopy analysis of cellular internalisation of FITC-albumin nanoparticles is 
shown in Figure 8. Strong green, FITC-associated fluorescence intensity signal can clearly be 
seen in the entire imaged area of the Caco-2 monolayer (Figure 8A). Furthermore, green 
fluorescence can be observed across the depth of the imaged cell monolayer area (shown by 
image orthogonal view or ‘z stacks’ in Figure 8B), suggesting fluorescence in the interior of 
the cells. 
 
Figure 8.  
 
Discussion  
The intestinal epithelium presents a significant barrier to oral delivery of biologics and 
nanomedicines for systemic effect. Despite the improved understanding of mucosal barrier 
homeostasis and recent advances in nanotechnology, technologies that safely and 
effectively surmount the intestinal epithelium, enabling oral delivery of complex therapeutics, 
are currently lacking. Transcytosis-enabled nanosystems have been proposed by several 
groups, including our own, for delivery of biomolecules or nanomedicines across the 
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mucosal surfaces of the airways [6-8] and the intestine [9-12]. Regarding oral delivery, these 
strategies have demonstrated that it is feasible to transport both biotherapeutics and 
nanoparticles across the intestinal mucosa and into the systemic circulation after oral 
administration [13-15]. However, none of these have progressed beyond the research stage.  
 
The challenge for clinical translation of nanomedicines for oral delivery is related to the 
complexity of the gastrointestinal system, namely the multicomponent nature of the intestinal 
barrier. Nanosystem delivery into the systemic circulation following ingestion requires 
stability in the digestive tract and penetration of additional, non-epithelial barriers, including 
the thick mucus layer and the basement membrane, above and below the epithelium, 
respectively. Assuming that all of these physiological factors have some effect on the overall 
nanoparticle translocation into the systemic circulation (resulting in drug loss), it is apparent 
that epithelial transcytosis pathway of choice should have a reasonable transport capacity if 
it is to present a viable strategy for the delivery of complex therapeutics across the 
gastrointestinal tract.  
 
Fabrication of transcytosis-exploiting nanosystems for oral delivery requires complex, 
multiconstituent systems, typically composed of the drug, the nanocarrier and the ligand 
directing the system to the transcytosis receptor of interest. This potentially increases the 
complexity of the system, presenting challenges in terms of formulation and stability of the 
system. In this respect, albumin nanoparticles are potentially interesting system as they may 
serve both as drug carriers and ‘transport-enabling’ entities – assuming they traverse the 
epithelium by transcytosis in the same manner as albumin in solution – hence removing the 
requirement for the ‘transport-enabling’ ligand. This would make the overall drug delivery 
system simpler and potentially more efficient. However, while albumin nanoparticles have 
demonstrated clear utility in the delivery of hydrophobic chemotherapeutic agents [16-19], 
attributed to features amenable to passive targeting via the enhanced permeability and 
retention (EPR) effect [16], studies that fully explore the potential of albumin nanoparticles 
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for oral delivery are limited to the use of bovine albumin, e.g. by coating as a ‘sacrificial’ 
component to protect drug degradation or provide nanosystem stability [20]. We explored 
whether albumin nanoparticles may be utilised as potential nanovehicles for oral therapeutic 
delivery based on: i) potential targeting of albumin transcytosis in the intestinal epithelium, 
and ii) the small size of albumin nanoparticles, achieved via a simple fabrication approach. 
The issue of stability of albumin nanoparticles in the gastrointestinal environment is 
appreciated, but the delivery of albumin nanoparticles to the intestinal mucosa is envisaged 
to take place via enteric delivery technologies, which are now well established.  
 
Albumin nanoparticles fabricated in this study displayed a size below 150 nm, low 
polydispersity and stability in a commonly used biological buffer, HBSS (Figure 1). 
Furthermore, apart from a single tested concentration, albumin nanoparticles did not exhibit 
toxicity towards Caco-2 cells (Figure 2).  
 
We subsequently confirmed FcRn expression in Caco-2 monolayers (Figure 3) as this 
receptor system is thought to play a key role in albumin uptake and transcytosis [21]. Our 
findings showing FcRn presence in intestinal Caco-2 cells confirm previous reports of its 
expression in the intestinal epithelium [22, 23]. A series of studies focused on probing the 
uptake and transepithelial transport of albumin in solution. The data in Figure 4 show that 
albumin uptake by Caco-2 monolayers is a saturable process, hence indicating a receptor-
mediated uptake. Albumin in solution form is capable of traversing the Caco-2 monolayers in 
a significantly more efficient manner than IgG as another FcRn ligand (68 ng versus 2.7 ng 
per 1.1 cm2 area) in a two-hour experiment (Figure 5).  
 
Importantly, the complete interactive interface for the FcRn-albumin interaction remains 
enigmatic and no in vitro cellular studies have so far demonstrated that FcRn can transport 
albumin efficiently in the presence of IgG across polarised cells [21]. Indeed, previous 
studies reporting on albumin transcytosis on intestinal epithelial cells are lacking. A rare and 
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recent study on this reported that albumin can be transcytosed across polarized T84 human 
intestinal epithelial cells, which express FcRn endogenously [24]. Furthermore, the rate of 
transcytosis was lower upon cell treatment with an antibody that blocks the albumin-binding 
site on FcRn, as well as for a mutant with no measurable binding to FcRn. We demonstrate 
for the first time that intestinal epithelial cell uptake and translocation of albumin is 
suppressed by co-application of IgG (Figure 6). This suggests FcRn involvement in the 
uptake and apical-to-basal transport of albumin by Caco-2 cells. Although FcRn binds both 
IgG and albumin at independent binding sites [19], FcRn-IgG interaction is likely to influence 
FcRn availability and engagement in albumin trafficking. Although albumin has been shown 
to interact with numerous cellular receptors, including glycoproteins Gp60, Gp30 and Gp18, 
secreted protein that is acidic and rich in cysteine (SPARC), and the cubilin complex, it has 
now become apparent that FcRn plays a fundamental role in homeostatic regulation of both 
IgG and albumin [21].  
 
The delivery potential of albumin nanoparticles was examined in Caco-2 monolayers by 
determining their cell uptake and transport across the cells, as well as establishing 
information on uptake behaviour. The data in Figure 7 show that cell uptake of albumin 
nanoparticles increased with application concentration, a trend not followed by albumin in 
solution. Furthermore, co-application of IgG did not attenuate the uptake of albumin 
nanoparticles, indicating that albumin nanoparticles follow a different trafficking route to 
albumin solution and that this route is not dependent on FcRn. This is also confirmed by 
data in Figure 6, whereby application of unlabelled albumin nanoparticles did not suppress 
the uptake of FITC-albumin in solution. Cell uptake of FITC-albumin nanoparticles was 
confirmed and shown convincingly by confocal microscopy, where fluorescence intensity of 
nanoparticles can clearly be seen in the cell interior (Figure 8). 
 
Comparing transport amounts between scenarios whereby albumin was applied in solution 
or as nanoparticles, it is apparent that a notably higher amount of albumin traverses the cell 
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monolayers following the application of albumin nanoparticles, as compared to albumin 
solution (380 ng versus 68 ng per 1.1 cm2 cell monolayer area; 5.6-fold difference). This is 
an important finding with regards to the system’s transport capacity, although it must be 
confirmed in vivo.  
 
Overall, our study demonstrates the potential of albumin nanoparticles, fabricated via a 
simple process, as drug delivery systems capable of traversing the intestinal epithelium. 
Although the mechanism of intestinal transit of these systems is not clear, work showed 
remarkable level of internalisation of albumin nanoparticles by intestinal Caco-2 cells and 
more efficient apical-to-basal mass transport of albumin when formulated as nanoparticles 
compared to the solution form. To fully evaluate the potential of this approach for oral 
delivery, the stability of albumin nanoparticles in different regions of the intestinal mucosa 
(e.g. colon versus small intestine), diffusion across the intestinal mucus, potential 
immunogenicity and the mechanism of trafficking by intestinal epithelial cells should be 
studied.  
 
In conclusion, this study is important as it highlights for the first time that simply-fabricated, 
non-toxic albumin nanoparticles show good uptake and permeation across the intestinal 
epithelial barrier and hence may find application in oral drug delivery.  
 
Summary Points 
 
• Human serum albumin nanoparticles, fabricated via a desolvation technique, had a 
diameter of approximately 150 nm 
• Albumin nanoparticle cell uptake and transport were compared with albumin solution 
in the Caco-2 intestinal model  
• Albumin nanoparticles were not toxic to Caco-2 cells at concentration below 140 
g/ml 
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• Caco-2 cells express neonatal Fc receptor (FcRn) 
• Albumin in solution form demonstrated cell uptake and transport behaviour 
suggesting involvement of FcRn (process was suppressed by co-application of FcRn 
ligand, IgG) 
• Albumin nanoparticles demonstrated behaviours indicating different cell uptake and 
transport pathways compared to albumin solution 
• Albumin transport was higher following application of equivalent concentration of 
nanoparticles compared to solution  
• The work suggests improvement of intestinal delivery of albumin by nanoformulation 
• Simply-fabricated, non-toxic human serum albumin nanoparticles may find 
application in oral drug delivery of poorly absorbed drugs  
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Figure legends  
 
Figure 1. Size stability of albumin nanoparticles over time in different environments. Size was 
characterised by dynamic light scattering (DLS) following incubation in water, phosphate buffered 
saline (PBS) and Hank’s Balanced Salt Solution (HBSS) for different periods of time. Data shown as 
mean ± SD of three separate measurements. Each individual measurement is in turn reported by the 
equipment as a mean of ten measurements. 
 
Figure 2. Effect of albumin nanoparticles on the viability of Caco-2 cells, measured by the MTS 
assay. Albumin nanoparticles were incubated with cells for three hours. Results presented as % 
viability relative to controls (Hank’s Balanced Salt Solution and Triton X-100) and expressed as the 
mean ± SD (n=6).  
 
Figure 3. Immunostaining for FcRn in polarised Caco-2 monolayers. A) Cells incubated with 
goat, anti-human FcRn (primary) antibody, followed by donkey, anti-goat TRITC-IgG (secondary 
antibody); i) Blue channel: cell nuclei stained with DAPI, ii) Red channel: TRITC fluorescence, and iii) 
Overlay image (Blue and Red channels). B) Immunostaining of cells in 3D. C) Control cells incubated 
with donkey, anti-goat TRITC-IgG (secondary antibody) only. DAPI: 4´,6-diamidino-2-phenylindole; 
TRITC: Tetramethylrhodamine isothiocyanate 
 
Figure 4. Uptake saturation of FITC-albumin by differentiated Caco-2 monolayers. FITC-albumin 
was applied to the apical side of Caco-2 monolayers in HBSS at 8 µg/ml, 40 µg/ml and 200 µg/ml for 
two hours. FITC-albumin uptake was measured following the permeabilisation of cells using Triton X-
100 (5% v/v; 10 min incubation) and determining the fluorescence intensity of the samples (n=3).  
 
Figure 5. Permeability of human serum FITC-albumin (‘Alb’) and human immunoglobulin G 
(IgG) across differentiated Caco-2 monolayers. FITC-albumin was applied at 40 µg/ml and 
sampled from the basal side every 20 min, whereas IgG was applied at 1 µg/ml, with 30 min sampling 
period. Data shown as the mean ± SD (n=3).  
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Figure 6. Albumin uptake and permeability competition studies. 40 µg/ml FITC-albumin solution 
was applied to polarised Caco-2 monolayers in combination with 100 µg/ml IgG or 140 µg/ml 
unlabelled albumin nanoparticles in HBSS. A) FITC-albumin uptake was measured by permeabilising 
the polarised Caco-2 cells using Triton X-100 (5% v/v; 10 min incubation) and quantitation by 
fluorescence. B) Apical-to-basal transport of FITC-albumin was determined by sampling the basal 
solution every 20 min and quantitation by fluorescence. Data shown as mean ± SD (n=3).  
 
Figure 7. Albumin nanoparticle uptake and transport across differentiated Caco-2 monolayers. 
FITC-albumin nanoparticles were applied at 40 µg/ml, with or without 100 µg/ml IgG, or at 200 µg/ml 
(albumin content) in HBSS. A) Nanoparticle uptake was determined following permeabilisation using 
Triton X-100 (5% v/v; 10 min incubation) and quantitation by fluorescence (n=3). B) Transepithelial 
transport was determined by regular sampling of the basal solution (every 20 min). Data shown as 
mean ± SD (n=3).  
 
Figure 8. Imaging of albumin nanoparticle uptake by Caco-2 cells. Confocal micrographs 
depicting Caco-2 monolayers treated with FITC-albumin nanoparticles, applied at 40 µg/ml. A) A 
single section of cell monolayer area. B) Orthogonal view showing the depth of the cell monolayer 
(constructed via imaging of a series of ‘z-stacks’). Blue: cell nuclei stained with DAPI; green: FITC-
albumin nanoparticles.  
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Figure 3.  
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Figure 5.  
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Figure 6.  
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Figure 7.  
 
 
Figure 8.  
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